On Friday, June 20, our Chief Scientific Officer, Dr. Melita Kaltak, will be speaking at the USH2025 Symposium.
Her talk, titled “Skipping a frequently mutated exon in USH2A as a therapeutic approach for USH2A-associated retinitis pigmentosa,” will close the session “Therapeutics II: Precision in reduction”. She will discuss our promising ASO-mediated exon skipping strategy and how it may help address one of the most common underlying causes of the disease.
If you are attending the symposium, don’t miss the chance to hear the latest updates from Astherna on developing targeted therapies for retinal diseases.
Related Posts
